secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001013762-23-002000
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron announces positive Phase 2a top-line results for Lomecel-B in mild Alzheimer's disease
--------------------------------------------------------------------------------

- Primary safety endpoint met; one SAE per Lomecel-B group, none on placebo, DSMB no issues.
- Secondary endpoint CADS showed statistical improvement for 25M single dose (p=0.091) and pooled groups (p=0.099) vs placebo at week 39.
- Lomecel-B low-dose (25M x1) significantly slowed left hippocampal volume loss (p=0.015) vs placebo.
- Pooled Lomecel-B groups showed significant improvement in ADCS-ADL (p=0.047) at week 39.
- Webcast and conference call held Oct 5, 2023 at 8:00 AM ET to discuss results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000101376223002000/0001013762-23-002000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000101376223002000/ea186354-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-002000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer